Pharmaceuticals

Rare Kidney Diseases Market Revenue Projected To Hit $20.7 Billion By 2030 With 5.8% CAGR

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Rare Kidney Diseases Market Be By 2030 Compared To Its 2026 Market Size?

The rare kidney diseases market has experienced significant growth in recent years. It is anticipated to expand from $3.03 billion in 2025 to $3.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.5%. The expansion observed historically is linked to factors such as limited therapeutic choices for rare renal conditions, increasing understanding of genetic kidney ailments, a rise in the occurrence of autoimmune-related nephropathies, the development of more nephrology specialty care centers, and the early implementation of immunosuppressive treatments.

The market for rare kidney diseases is projected to experience substantial expansion over the upcoming years, anticipated to reach a valuation of $4.88 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. This projected growth during the forecast period is fueled by several factors, including advancements in genomics-based drug discovery, an increase in orphan drug approvals, greater investment in rare disease research, the expanding adoption of personalized medicine approaches, and a growing pipeline of complement and immune-targeted therapies. Key trends anticipated within the forecast timeframe encompass an escalating focus on targeted therapies for rare renal conditions, heightened clinical trial activity for orphan kidney medications, wider adoption of biologics in immune-mediated kidney ailments, the broadened use of companion diagnostics for early disease identification, and enhanced regulatory incentives for developing drugs for rare diseases.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

Which Major Drivers Are Influencing The Expansion Of The Rare Kidney Diseases Market?

The rising occurrence of chronic kidney disease (CKD) substantially influences the rare kidney disease market. This condition describes impaired kidneys that cannot effectively cleanse the blood. A higher incidence of chronic kidney diseases leads to an elevated risk of patients developing rare kidney diseases, thereby boosting the need for related treatments. As an illustration, in August 2025, the US-based voluntary nonprofit health organization, National Kidney Foundation, Inc., reported that the Senate endorsed an additional $5 million in the FY 2026 Labor, Health and Human Services, and Education appropriations bill, designated for advancing kidney transplant reform and early detection initiatives. This augmentation raises the overall funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative to $59 million. Consequently, the growing occurrence of chronic kidney disease (CKD) will propel the rare kidney disease market.

What Are The Different Segment Types In The Rare Kidney Diseases Market Segment Breakdown?

The rare kidney diseases market covered in this report is segmented –

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications

2) By Type Of Molecule: Small Molecules, Biologics

3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management

2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics

3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents

4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies

5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies

6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders

Which Trends Are Guiding The Direction Of The Rare Kidney Diseases Market?

Leading companies in the rare kidney diseases market are concentrating on developing non-immunosuppressive treatments for these conditions. This unique therapeutic approach offers a solution for patients with progressive kidney diseases, a capability not shared by conventional therapies for rare kidney conditions. An example of this is the launch of sparsentan, marketed as Filspari, by Travere Therapeutics, a US-based biopharmaceutical company, in February 2023. Filspari represents the initial non-immunosuppressive treatment sanctioned for primary immunoglobulin A nephropathy (IgAN). Its distinct mechanism of action involves blocking angiotensin and endothelin receptors. This characteristic distinguishes Filspari from established angiotensin-targeting medications like ACE inhibitors and ARBs, which are commonly used for hypertension but have been adapted for IgAN management because of their ability to reduce renal blood pressure.

Who Are The Well-Known Companies In The Rare Kidney Diseases Market?

Major companies operating in the rare kidney diseases market are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc.

Get The Full Rare Kidney Diseases Market Report:

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Which Region Is The Top Contributor To The Rare Kidney Diseases Market By Share?

North America was the leading region in the rare kidney disease market in 2025. The regions covered in the rare kidney diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Rare Kidney Diseases Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Browse Through More Reports Similar to the Global Rare Kidney Diseases Market 2026, By The Business Research Company

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795